Exploring Space as the Next Frontier for Biopharma R&D: Maureen Haverty, Seraphim Space/Generation Space

·30 min·2 clips

Voyager Space, Space Pharma, URI, and Prometheus are each building different life-sciences-in-space bets.

1. The Real Chemistry Podcast episode centers on Maureen Haverty and the claim that space is becoming a practical frontier for biopharma R&D. 2. Aaron Strout, Real Chemistry’s chief marketing officer and host, interviews Haverty, the VP of Investment at Seraphim Space and Generation Space, because her role spans deep tech and venture investing. 3. The episode asks what space can actually do for life sciences now, not in theory, and why the timing matters for investors. 4. Haverty says her path into space was “incredibly circuitous,” starting with a PhD in nuclear engineering and research on nuclear fuel performance in the UK. 5. She describes joining Apollo Fusion, where she worked on a fission blanket around a fusion core before the company pivoted into satellite propulsion in 2017. 6. She says that pivot happened because the team could not meet its neutron-generation commitments for fusion without making a false promise to investors. 7. Haverty explains that Apollo Fusion later became part of Astra during the 2021 SPAC boom, and she moved into corporate development before joining Seraphim Space. 8. She clarifies that Seraphim Space and Generation Space are the same company, with Seraphim Space used outside the U.S. and Generation Space used in the U.S. 9. She adds that the company opened a San Francisco office in 2022 and runs an accelerator for U.S. and Canadian startups there. 10. Haverty says space investing looks attractive because launch costs have fallen, launches are more frequent, and startups now lead what she calls “new space.” 11. She notes that rideshare access and companies like Spaceflight make it easier to launch satellites without relying on one expensive, one-off mission. 12. She says cheaper access lets builders use automotive parts in satellites and still achieve better performance than older components. 13. She explains that more satellites also support better Earth imaging, communications direct to phones, and climate data collection. 14. On debris, she says low Earth orbit objects usually burn up within months to 25 years, and the U.S. FCC now requires de-orbiting within five years. 15. She argues that debris from intentional satellite destruction is a bigger danger than routine satellite congestion. 16. On life sciences, Haverty separates astronaut healthcare from R&D and manufacturing, and says the second category is the more venture-scale opportunity. 17. She says microgravity can change bacteria, fluid behavior, and protein crystallization, which matters for synthetic biology, drug delivery, and organ growth. 18. She names Merck, Pfizer, and AstraZeneca as companies that have done research on the International Space Station, and cites Merck’s Keytruda-related work in Nature Microgravity. 19. The interview is structured, explanatory, and technical, with Aaron pushing for plain-language examples and Haverty answering in company names, timelines, and regulatory details. 20. Listeners interested in biotech strategy, deep-tech investing, or space infrastructure will get the most value, while anyone wanting a light, non-technical chat may skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Real Chemistry Podcast